Reporting status: September 28, 2026. This is a developing story. The distinction between a searched property and a related business matters; an investigation does not establish wrongdoing. For research and educational purposes only; not legal advice.
TL;DR
On September 23, 2026, a multi-agency team led by the U.S. Postal Inspection Service searched a business at 503 Prosperity Way in North Sioux City, South Dakota and a residential property in Dakota Dunes at roughly the same time. The searched business, Apex Waste Management, shares its registered address and ownership with several other entities, including the research peptide vendor Apex Peptides. As of September 28, 2026, no charges have been publicly filed, no warrant has been unsealed, no agency has issued a statement naming Apex Peptides specifically, and the FDA's warning-letter database contains no letter addressed to Apex Peptides. The company's website went to a temporarily-closed state after the search, with most products removed. Two people were reportedly escorted in handcuffs on the day of the search, according to local TV stations KSCJ and KCAU. No arrests have been officially confirmed. This is a developing story with significant confirmed facts and significant open questions. This article covers both, clearly separated.
What Is Confirmed: The Facts Local Reporting Has Established
On September 23, 2026, more than a dozen marked and unmarked law enforcement vehicles arrived at 503 Prosperity Way in North Sioux City, South Dakota around 10 a.m. local time. The operation was led by the U.S. Postal Inspection Service (Minneapolis field office), with assistance from the FBI (agents from both Omaha and Minneapolis offices), IRS Criminal Investigation, the Union County Sheriff's Office, and North Sioux City Police. Federal agents spent most of the day at the property and cleared the scene by late afternoon. (KTIV's on-scene account; KCAU's agency report)
Simultaneously, Postal Inspection Service agents conducted a search at 661 Prairie Boulevard in Dakota Dunes, a residential property owned by Ryan Isaacson according to Union County property records. Agents removed multiple bags and boxes from the home. Ryan Isaacson is the twin brother of Riley Isaacson, who is named in South Dakota business filings as president of Apex Waste Management and Apex Research, two of the entities registered at 503 Prosperity Way.
Around noon, a UPS driver arrived at the business during the search. Federal agents met him and directed him to pull behind the building, where they unloaded his delivery directly into a U-Haul truck already being used to collect seized items.
South Dakota Secretary of State records, as reported by KTIV, show approximately two dozen businesses affiliated with the Prosperity Way address and connected to owners Jared Miller and Riley Isaacson. Among those businesses: Apex Peptides, Apex Waste Management, Apex Research, Apex Outdoor Pros, Apex Rx, Apex Assure, Apex Cosmetics, and Apex Threadhaus and Ink. Apex Peptides, Apex Waste Management, and Apex Research also list a Sergeant Bluff, Iowa address as their primary location per KTIV's reporting. (KTIV's business-records follow-up)
The Better Business Bureau identifies Jared Miller as the customer contact for Apex Peptides, with a listed address of 503 Prosperity Way. This corporate overlap is the documented basis for the connection between the searched property and Apex Peptides.
Before the September 23 search, investigative reporting by Myranda Polisci (Substack) indicates that U.S. Postal Service and Department of Homeland Security officials had intercepted a package bound for a Dakota Dunes, South Dakota address during the winter of 2026, and that at least two local sources provided information to federal investigators several months before the raid. Canada and Australia had also separately intercepted peptide shipments before the U.S. action took place. (Myranda Polisci's investigation)
Following the search, Apex Peptides' website went to a temporary closure state and most products were removed from the site. One product reportedly remained listed.
What Is NOT Confirmed: The Open Questions That Matter
This is where precision becomes critical, and where much of the coverage on this story has been less careful than researchers deserve.
As of September 28, 2026, no news outlet or public record has confirmed that Apex Peptides itself was searched. KTIV, the primary local outlet covering this story, explicitly noted that it did not report that Apex Peptides was searched. The confirmed searches occurred at Apex Waste Management's property and at Ryan Isaacson's residence.
No charges have been publicly filed. No warrant has been unsealed. No agency, including the U.S. Postal Inspection Service, the FBI, IRS Criminal Investigation, or the U.S. Attorney's offices for the Districts of South Dakota or the Northern District of Iowa, has issued a public statement naming Apex Peptides, any individual by name, or describing the subject matter of the investigation.
The FDA's warning-letter database contained no letter addressed to Apex Peptides when checked on September 24, 25, and 26, 2026 by multiple independent sources. FDA agents have not been confirmed at the scene by any outlet. (FDA warning-letter database)
The specific charges or allegations being investigated have not been publicly disclosed. The search warrant affidavit, which would describe the probable cause that led to the searches, has not been made public.
The agency profile of this investigation is worth noting carefully. The U.S. Postal Inspection Service investigates crimes involving the U.S. mail system, including mail fraud, shipping of prohibited materials, and related offenses. IRS Criminal Investigation focuses on financial crimes including tax evasion, money laundering, and structuring. FBI involvement is consistent with complex financial fraud cases. This combination reads more like a financial crimes and mail fraud investigation profile than a product-focused FDA enforcement action. Whether peptides are the primary subject, a secondary element, or even incidental to the investigation has not been established.
The Enforcement Context: How This Fits the 2025-2026 Pattern
Regardless of what is ultimately determined to be the subject of the Apex-linked searches, the event lands in the middle of the most significant enforcement period the research peptide sector has seen in its history.
The documented timeline looks like this:
- December 2024. FDA issues warning letters to Prime Peptides, Xcel Peptides, SwissChems, and Summit Research in a coordinated initial enforcement action. The letters cited marketing peptides as drugs for human use without an approved NDA.
- June 2025. FDA raids the Amino Asylum warehouse. The site goes offline. Amino Asylum had received prior warning letters but continued operating. Critically, their catalog included compounds with prescription drug status sold alongside research-labeled compounds, and they had made therapeutic claims in their marketing.
- September 2025. FDA issues more than 50 warning letters to companies compounding or manufacturing semaglutide and tirzepatide, targeting the GLP-1 compounding market directly.
- December 2025. Paradigm Peptides founders plead guilty to federal charges. Matthew Kawa pled guilty in connection with SARMs products found to contain undisclosed testosterone. The Paradigm case is notable because the prosecution was driven not by peptide sales alone but by the presence of undisclosed controlled substances in products marketed as SARMs.
- March 2026. Peptide Sciences closes voluntarily. The company issued a three-sentence notice and stopped accepting orders without providing a detailed public explanation. No FDA warning letter to Peptide Sciences has been confirmed.
- March 2026. HHS Secretary Kennedy announces that approximately 14 peptides previously on the restricted compounding list would be reconsidered for supervised access, signaling a policy shift at the executive level.
- July 2026. The FDA's Pharmacy Compounding Advisory Committee votes to recommend BPC-157 (8-6), TB-500 (8-6), KPV (8-6), MOTS-c (7-5), Semax (narrow majority), and Epitalon (narrow majority) for inclusion on the 503A Bulk Drug Substances List. Emideltide (DSIP) was rejected 7-6. These are non-binding recommendations; actual rulemaking is estimated at 12 to 24 months.
- July 2026. Paradigm Peptides founder sentenced to 70 months in federal prison.
September 15, 2026. Eternal Peptides voluntarily closes following a closing sale.
September 23, 2026. Apex-linked properties searched.
The pattern across confirmed enforcement actions shares common threads. Amino Asylum made therapeutic claims, sold prescription medications, and ignored warning letters. Paradigm Peptides sold SARMs products containing undisclosed controlled substances. The FDA's enforcement focus has been on conduct that crosses identifiable legal lines: prescription drug sales without an NDA, misbranded products, therapeutic marketing, undisclosed controlled substances. The cited cases involved conduct beyond RUO labeling, but labeling alone does not establish that a vendor is compliant.
What the Apex situation has in common with those cases is unknown, because the investigation has not been characterized publicly.
The International Dimension
One detail in the pre-raid reporting deserves specific attention for researchers who order from vendors with overseas supply chains.
Investigative reporting indicates that Canadian and Australian authorities intercepted peptide shipments before the September 23 U.S. action. This cross-border dimension, combined with the USPIS and DHS involvement in package interception as far back as winter 2026, suggests investigators were building a case over months and tracking international supply movement before the searches occurred.
This is a different operational profile than the FDA-led enforcement actions that have characterized most of the 2024-2026 enforcement wave, and it lines up more closely with postal inspection investigations into mail fraud or illegal importation. What was in those intercepted packages, and whether peptides were confirmed contents, has not been established in public reporting.
What This Means for Researchers and the RUO Sector
The honest answer is less alarming than headlines suggest, and more serious than dismissing it would imply.
Less alarming because the Apex situation is genuinely unresolved. No charges, no warrant, no subject matter confirmation. The USPIS-led, IRS-CI-assisted investigation profile with international package interception history reads more like financial fraud and mail fraud than a direct FDA product enforcement action. Commentary suggesting this is the FDA coming for RUO researchers is not supported by confirmed facts.
More serious because the enforcement environment is real and documented. Multiple research peptide vendors have closed since mid-2025, while some separate enforcement cases have resulted in federal criminal proceedings. The common factor across confirmed enforcement actions was not RUO labeling per se but specific conduct: therapeutic marketing claims, selling prescription drugs, misrepresenting product contents, undisclosed controlled substances. Vendors maintaining strict RUO documentation, legitimate third-party COAs from named independent laboratories, and consistent avoidance of therapeutic marketing claims are operating in a meaningfully different risk environment than the companies that have faced confirmed enforcement.
The July 2026 PCAC recommendations remain the most consequential regulatory development of the year. Six substances received advisory recommendations for a potential compounding pathway; those votes did not themselves authorize compounding. That process is independent of enforcement actions against individual vendors and represents a genuine pathway toward legitimized research access for the compounds most widely studied by this community. See the PCAC decision and regulatory roadmap.
The two things that can be true simultaneously: enforcement is real, and a documentation-forward, compliance-focused RUO vendor is a different risk profile than the companies that have faced confirmed enforcement actions.
What Vendors in the Active Directory Have in Common
Every vendor in the RUOcodes.com directory meets a documented minimum testing standard that goes beyond RUO labeling. The minimum requirements include third-party mass spectrometry identification, HPLC purity testing, and endotoxin documentation from named independent laboratories. That standard was established precisely because the enforcement environment makes documentation the baseline difference between a vendor operating defensibly and one that isn't.
The Apex situation has not changed those standards. It has reinforced why they matter.
What to Watch For
The sealed search warrant, if and when it becomes public, will be the most informative document to emerge from this situation. Search warrant affidavits describe the probable cause that led to the search and typically identify the alleged conduct being investigated. When that document becomes available, many of the open questions above will be answered.
Official charging documents, if filed, will establish what specifically is alleged. The absence of public charges five days after the search is not unusual for federal investigations, which can take months or longer to produce indictments after a search warrant is executed.
Whether Apex Peptides resumes operations, issues a public statement, or makes any communication will also be significant. The current temporary closure and product removal suggest the principals are not in a position to operate normally, but that fact alone does not establish specific charges.
This article will be updated as confirmed information becomes available. For real-time coverage of this story, follow local Sioux City news from KTIV (ktiv.com), KCAU 9 (keloland.com/kcau), and KSCJ, which have been the most accurate and most careful in separating confirmed facts from speculation. For deeper investigative context, Myranda Polisci's Substack (myrandapolisci.substack.com) has produced the most detailed pre-raid corporate structure reporting.
A Note on Sourcing Standards
Several outlets and community posts covering this story have presented unconfirmed allegations as established facts. This article has cited only what has been confirmed by named local news outlets physically present at the scene (KTIV, KCAU, KSCJ, KELO), documented by official records such as South Dakota Secretary of State filings and Union County property records, confirmed by direct checks of the FDA warning-letter database, or sourced from named investigative journalists with documented primary sources.
The research community deserves accurate information, especially on a story with direct implications for sourcing decisions. The confirmed facts of this situation are significant enough without embellishment.
For the vetted vendor directory, COA documentation standards, and active sourcing information with verified current codes, see ruocodes.com. Every vendor listed in the directory meets a documented minimum testing standard evaluated against criteria that go beyond RUO labeling alone.
Primary reporting and reference documents
- KTIV: Federal agents search North Sioux City business and Dakota Dunes home (September 23, 2026)
- KTIV: Additional businesses tied to the searched address (September 25, 2026)
- KCAU 9: IRS Criminal Investigation at North Sioux City business (September 23, 2026)
- KELO: A Sioux City Business Was Raided Yesterday (September 24, 2026)
- Myranda Polisci: Federal Investigators Raided North Sioux City (September 23, 2026; investigative reporting, distinguish its claims from confirmed agency findings)
- FDA: July 23–24, 2026 Pharmacy Compounding Advisory Committee materials (regulatory context; unrelated to the September searches)
- FDA: Warning Letters database (check individual letters and dates directly)
Related research resources
For the separate regulatory debate, see our FDA PCAC peptide-vote roadmap. For supplier due diligence, read how to evaluate a research peptide supplier, RUO Codes' vendor standards, and the vetted vendor directory.
For research and educational purposes only. Not legal advice. Regulatory context and reporting reviewed September 28, 2026. New official documents may change what is known.